Production (Stage)
Inhibikase Therapeutics, Inc.
IKT
$1.95
-$0.01-0.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.68M | -12.13M | -5.78M | -4.96M | -4.65M |
| Total Depreciation and Amortization | 12.70K | 6.60K | 6.60K | 6.60K | 6.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.23M | 7.91M | 148.00K | 30.70K | 53.40K |
| Change in Net Operating Assets | 1.33M | -1.13M | 742.40K | -132.00K | 722.60K |
| Cash from Operations | -4.10M | -5.35M | -4.88M | -5.05M | -3.87M |
| Capital Expenditure | -13.40K | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 21.07M | -38.76M | 2.53M | 2.54M | -3.31M |
| Cash from Investing | 21.05M | -38.76M | 2.53M | 2.54M | -3.31M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 99.68M | 182.00K | 3.21M | 397.60K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 30.60K | -30.60K |
| Cash from Financing | -- | 99.68M | 182.00K | 3.24M | 367.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.95M | 55.58M | -2.17M | 733.10K | -6.81M |